Roles of Extracellular Vesicles in Cancer Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 91
Special Issue Editors
Interests: cancer biology; cell proliferation; Chinese herbal medicine
Special Issue Information
Dear Colleagues,
Extracellular vesicles (EVs) have emerged as crucial players in cancer immunotherapy, holding great promises for revolutionizing the way for cancer treatment. These nanoscale, membrane-bound structures secreted by various cell types play multifaceted roles in both promoting and suppressing tumor growth, as well as in shaping the immune response.
Tumor cells often release EVs loaded with immunosuppressive molecules, such as PD-L1, which can inhibit T-cell activation and promote tumor evasion. Tumor-derived EVs can also facilitate metastasis by creating a favorable pre-metastatic niche in distant organs. Meanwhile, EVs derived from immune cells, such as dendritic cells, can carry tumor antigens to stimulate an anti-tumor immune response. Certain immune cell-derived EVs can enhance or suppress the immune response, depending on their cargo and the recipient cell.
EVs can be engineered to encapsulate and deliver therapeutic agents to tumor cells directly, such as chemotherapeutic drugs or immune-stimulating molecules. EVs loaded with tumor antigens can be used as therapeutic vaccines to prime the immune system against cancer. Additionally, EVs present in body fluids can also serve as potential biomarkers for cancer diagnosis and prognosis.
This Special Issue aims to elaborate the diverse roles of EVs in cancer immunity and prospect the potential therapeutic applications in cancer immunotherapy.
Dr. Shujing Liu
Dr. Zhiyuan Qin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- extracellular vesicles
- microvesicles
- exosomes
- cancer biology
- cancer immunity
- cancer immunotherapy
- biomarkers
- cancer vaccines
- antigen presentation
- drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
